The Shared Investigator Platform will be built as an ‘industry utility’ to bring standardization and consistency to clinical trials. Investigator platforms are often deployed by each pharmaceutical company, resulting in clinical sites using multiple environments, which adds complexity and risk.
The new platform aims to enhance organizational productivity by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy, and reducing study start-up time. It also aims to help pharma companies to improve quality, regulatory compliance, process visibility, and capacity, while reducing investigator efforts related to training, document exchange, and support.
“This collaboration is an important part of TransCelerate’s strategy to improve clinical trial processes in order to bring innovative new medicines to patients faster,” said Jackie Kent, senior director, Clinical Development Information and Optimization, Eli Lilly & Co., and Shared Investigator Platform Leader, TransCelerate. “The Shared Investigator Platform will benefit sites by simplifying processes, and reducing time and effort spent on standard study activities.”
“We are pleased to partner with TransCelerate to build this first-of-a-kind platform, which will help maximize the potential of technology-based collaboration and provide better medicines to patients, greater efficiency to clinical sites, and superior business outcomes to pharmaceutical sponsors,” said Bhaskar Sambasivan, vice president of Cognizant’s Life Sciences practice. “Streamlining the clinical trials process will enable TransCelerate’s member companies to speed drug development and drive innovation in improving patient health.”